I M M U L I T E. DPC s Third Generation PSA Assay. The Clinician s Choice for PSA Testing. D P C T e c h n i c a l R e p o r t
|
|
- Earl Powell
- 6 years ago
- Views:
Transcription
1 D P C T e c h n i c a l R e p o r t I M M U L I T E DPC s Third Generation PSA Assay The Clinician s Choice for PSA Testing Jonathan McDermed, Pharm.D. Marketing Manager, Corporate Marketing
2 DPC s Third Generation PSA Assay: The Clinician s Choice for PSA Testing DPC s Third Generation PSA assay gives clinicians the ability to use one PSA test for all patient applications. It has assumed an indispensable role within the realm of therapeutic PSA monitoring, prostate cancer therapy optimization and outcome prediction due to its precision at very low serum concentrations. In addition to providing accurate and timely quantification of PSA levels during and after therapy, DPC s Third Generation PSA assay is also well suited for general prostate cancer screening purposes. Prostate cancer screening controversy According to the American Cancer Society (ACS), men aged 50 and older who receive an annual medical examination should be offered a digital rectal examination and a PSA test. 1 The ACS also recommends that men aged 40 and over be informed about the risk of prostate cancer 2 and that screening be considered at an earlier age, such as 40 or 45, in high-risk individuals, e.g., African-Americans and first-degree relatives of prostate cancer patients. In contrast, a number of physician organizations do not advocate routine screening. 3,4 This position is based on their claims that there is no conclusive evidence that early detection and treatment influence the overall death rate from this disease, 5 and that the standard treatment (radical prostatectomy) is associated with a high incidence of side effects. 6 Despite the conflicting recommendations, PSA testing has increased rapidly among asymptomatic men in the US, 7 and ACS statistics show a remarkable decline in the death rate from prostate cancer over the past 5 years (Figure 1). 8 Fi g u re 1. Five-year trends in prostate cancer. Based on collated mortality statistics from the A m e r i c a n Cancer Society. 8 Other technologies may also be contributing to earlier detection of prostate cancer. These include the availability of free PSA and use of the free-to-total PSA ratio; improved ultrasonography and prostate biopsy methods; and the wider application of risk assessment algorithms involving, for example, age-adjusted PSA, prostate gland volume, transition zone volume and PSA density. The decline in prostate cancer mortality may also be explained, in part, by improved treatments for early-stage disease and better follow-up care, as reviewed below. Current PSA studies indicate that cancer cases exhibit a slow linear PSA phase initially, followed by a rapid exponential phase, and that PSA levels begin to increase exponentially approximately 7 to 9 years before diagnosis. 9 Experts agree on the benefits of calculating PSA doubling times (PSADT), which are derived from a baseline measurement and subsequent PSA values obtained at appropriate intervals. Published data indicate that the median PSADT for localized prostate cancer is 4 years, but it is shorter in higher clinical stages and worse histologic grades. 10,11 In contrast, PSADT in agematched controls is much longer. 12 Because the IMMULITE and IMMULITE 2000 Third Generation PSA assays possess outstanding low-end precision, they are ideal tools for following PSA trends over time and obtaining accurate PSADT calculations. Monitoring treatment The most generally useful clinical application of PSA determinations is in the monitoring of treated prostate cancer patients. Treatments include (radical) prostatectomy, radiation therapy, and hormonal therapies involving medical or surgical castration. Circulating PSA levels can provide invaluable information about the effectiveness of the therapy used and the existence of residual cancer, as well as early detection of cancer recurrence. Rising PSA levels can signal cancer activity well before any clinical signs of recurrence appear. This lead time can be further increased by months or even years when using ultrasensitive PSA immunoassays such as the IMMULITE and IMMULITE 2000 Third Generation PSA assays. The expected PSA results associated with good outcomes following various prostate cancer treatments are listed in Table 1. Studies using DPC s Third Generation PSA assays have established the value of highly sensitive PSA assays to detect early prostate cancer relapse following radical prostatectomy Witherspoon et al. demonstrated an average 18-month lead time in detecting disease progression using DPC s IMMULITE Third Generation PSA compared to a conventional PSA assay (Figure 2). 13 Vassilikos et al. confirmed this lead time and was able, over a 4-year follow-up period, to define a group of patients having rapid PSA relapse. 14 Doherty et al. showed that a single baseline PSA level < 0.01 µg/l measured 4 to 6 weeks postsurgery indicates a lower probability of disease progression. 15 On multivariate analysis, failing to achieve a PSA nadir of < 0.01 µg/l was found to be an independent predictor of relapse, and a stronger factor than even the Gleason sum or pathological margin status. 1
3 Table 1. Relevant PSA values in various treatment modalities. Definitive radiation therapy in which the gland remains in situ rarely results in an undetectable PSA, even when cure is achieved. 19 However, there is a general consensus that PSA levels reaching a nadir < 1.0 µg/l are associated with improved biochemical disease-free survival. 16,17 Disease progression is strongly suspected if the PSA rises on consecutive determinations. The use of a highly sensitive PSA assay, such as the IMMULITE or IMMULITE 2000 Third Generation PSA, can help detect early disease progression in radiationtreated patients. For patients suffering PSA progression following primary surgery, viable treatment options include salvage radiation or androgen deprivation therapy (ADT). Salvage radiation treatment will benefit only those patients with proven residual cancer in the prostatic fossa, whereas ADT can benefit those with residual cancer and/or metastatic disease. Serial PSA measurements in the months following surgery can be used to determine whether a patient is more or less likely to benefit from salvage radiation therapy For example, undetectable baseline PSA levels (defined by conventional assays as < 0.2 µg/l following surgery), which later become detectable and progressively rise, suggest locally recurring cancer in the prostatic fossa. 18 (See Figure 2 for an example.) On the other hand, detectable PSA levels at baseline which show progressive increases may represent microscopic metastatic disease that was present prior to radical prostatectomy. In the former scenario, salvage radiation treatment may be indicated, whereas systemic salvage treatment using ADT would appear to be indicated in the latter. Early PSA relapse, unfavorable Gleason sum and rapid PSADT are also associated with prostate cancer metastases following both surgery and radiation treatment. 26,27 The lead time 2
4 afforded by ultrasensitive PSA assays and their superior lowend precision identifies patients with early disease relapse and can help guide medical decision-making regarding salvage therapy options. Figure 2. Postoperative PSA levels over time in a 73-yearold man who underwent radical prostatectomy. No tumor was present at the surgical margins, seminal vesicles or regional lymph nodes; and the postoperative baseline PSA was µg/l. PSA at 4.2 years after prostatectomy became detectable at 0.10 µg/l using a conventional PSA assay. Using the IMMULITE Third Generation PSA assay, a PSA rise was observed 2 years earlier. 13 For primary or salvage ADT, PSA is the most sensitive surrogate marker of disease activity with which to judge treatment efficacy. Even in advanced metastatic disease, achieving an undetectable PSA < 0.2 or < 0.3 mg/l within 6 months of starting ADT distinguishes patients with a favorable and persisting response to ADT from those in whom only a limited response can be expected. 21,28 For patients with less extensive disease, response to ADT is likely to be extremely favorable. 22 Attainment and maintenance of a PSA < 0.05 µg/l for a year or more while on ADT can be used to identify patients with androgen-dependent prostate cancer, in whom intermittent ADT is feasible Using intermittent ADT, patients with low-volume disease, such as those having PSA relapse, can often enjoy prolonged time-off treatment with improved quality of life. 25 When retreatment is indicated in such patients, due to a rising PSA or other clinical findings, an excellent response to ADT can be anticipated (Figure 3). Figure 3. Time course of PSA and testosterone levels in a 65-year-old patient with stage T2a prostate cancer (Gleason sum = 5 disease) treated with intermittent androgen deprivation (IAD). Because therapy induced a rapid decline in circulating PSA to persistently undetectable levels ( 0.01), androgen deprivation was suspended in late 1997 and the subsequent rise in PSA was monitored. When therapy was reinstated three years later, PSA levels again dropped rapidly to undetectable levels. (Testosterone was measured periodically to check the impact of therapy on circulating androgen levels.) Conclusion It has become essential for all-purpose PSA assays to have third-generation capability. DPC s Third Generation PSA assays effectively address the requirements of modern prostate cancer treatment modalities by providing extraordinary analytical sensitivity with excellent precision at very low concentrations. At the same time, their working range easily accommodates PSA values for general prostate cancer screening purposes. References 1. American Cancer Society. Man to man newsletter. The PSA blood test and prostate cancer. Atlanta, GA: The Society, American Foundation for Urologic Disease. Prostate cancer resource guide. Baltimore, MD: The Foundation, US Preventative Services Task Force. Guide to clinical preventive services. 2nd ed. Washington, DC: US Dept. of HHS, PHS, Science, Office of Disease Prevention and Health Promotion, Inc., American Cancer Society: Prostate cancer and cancer detection guidelines, Atlanta, GA: The Society, Centers for Disease Control and Prevention. Screening with the prostate-specific antigen test Texas Morbid Mortal Weekly Rep 2000 Sept 15;49(36). 3
5 6. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000 Jan 19;283(3): Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995 Feb 15;273(7): American Cancer Society. Mortality Statistics, From the Web site of the American Cancer Society: 9. Crawford ED, DeAntoni EP, Ross CA. The role of prostate-specific antigen in the chemoprevention of prostate cancer. J Cell Biochem Suppl 1996;25: el-galley RE, Petros JA, Sanders WH, Keane TE, Galloway NT, Cooner WH, et al. Normal range prostate specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology 1995 Aug;46(2): Schmid HP. Tumour markers in patients on deferred treatment: prostate specific antigen doubling times. Cancer Surv 1995;23: Carter HB, Pearson JD, Metter EJ. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267(16): Witherspoon LR, Lapeyrolerie T. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol 1997 Apr;157(4): Vassilikos EJ, Yu H, Trachtenberg J, Nam RK, Narod SA, Bromberg IL, Diamandis EP. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clin Biochem 2000 Mar;33(2): Doherty AP, Bower M, Smith GL, Miano R, Mannion EM, Mitchell H, et al. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer 2000 Dec;83(11): Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 1998 Jan;51(1): Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist 2000;5(1): Fowler JE Jr, Pandey P, Braswell NT, Seaver L. Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer. Surgery 1994 Aug;116(2):302-5; discussion Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 May 5;281(17): Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 1989 May;141(5): Egawa S, Matsumoto K, Suyama K, Soh S, Kuwao S, Iwamura M. Limited suppression of prostate-specific antigen after salvage radiotherapy for its isolated elevation after radical prostatectomy. Urology 1999 Jan;53(1): Zagars GK, Sands ME, Pollack A, von Eschenbach AC. Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome. J Urol 1994 May;151(5): Fowler JE Jr, Pandey P, Seaver LE, Feliz TP, Braswell NT. Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. J Urol 1995 Jun;153(6): Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996 Nov;48(5): Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J Urol 1996 Aug;156(2 Pt 1): Aref I, Eapen L, Agboola O, Cross P. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma. Radiother Oncol 1998 Aug;48(2): Cadeddu JA, Partin AW, DeWeese TL, Walsh PC. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998 Jan;159(1):173-7; discussion Forman JD, Meetze K, Pontes E, Wood DP Jr, Shamsa F, Rana T, et al. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol 1997 Oct;158(4):1436-9; discussion
6 ZB207 A 2001 DPC All Rights Reserved Diagnostic Products Corporation 5700 West 96th Street Los Angeles, CA Tel: Tel: Fax: info@dpconline.com Web site:
When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationPost Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series
Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka
More informationPROSTATE-SPECIFIC ANTIGEN (PSA) is a sensitive
Prostate-Specific Antigen Doubling Times Are Similar in Patients With Recurrence After Radical Prostatectomy or Radiotherapy: A Novel Analysis By Bryan D. Leibman, Ozdal Dillioglugil, Peter T. Scardino,
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationThe Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationTREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER: QUALITY-ADJUSTED LIFE YEARS AND THE EFFECTS OF LEAD-TIME
ADULT UROLOGY TREATMENT OPTIONS FOR LOCALIZED PROSTATE CANCER: QUALITY-ADJUSTED LIFE YEARS AND THE EFFECTS OF LEAD-TIME VIBHA BHATNAGAR, SUSAN T. STEWART, WILLIAM W. BONNEY, AND ROBERT M. KAPLAN ABSTRACT
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationNICE BULLETIN Diagnosis & treatment of prostate cancer
Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationOne of the most important clinical applications of
PII S0009-9120(99)00099-5 Clinical Biochemistry, Vol. 33, No. 2, 115 123, 2000 Copyright 2000 The Canadian Society of Clinical Chemists Printed in the USA. All rights reserved 0009-9120/00/$ see front
More informationPCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS
Volume 70 July - August 2011 PCa Commentary SEATTLE PROSTATE INSTITUTE CONTENTS TESTOSTERONE REPLACEMENT in Hypogonadal Men with Treated and Untreated Prostate Cancer? 1 TESTOSTERONE REPLACEMENT in Hypogonadal
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationSerum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate
Article ID: WMC003222 ISSN 2046-1690 Serum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate Corresponding Author: Mr.
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationRadiation therapy after radical prostatectomy: A single-centre radiation oncology experience in trends of referral and treatment practices
Original original research Radiation therapy after radical prostatectomy: A single-centre radiation oncology experience in trends of referral and treatment practices Michel Zimmermann, MD; * Daniel Taussky,
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationof Nebraska - Lincoln
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Department of Veterans Affairs Staff Publications U.S. Department of Veterans Affairs 8-2000 Detection, Characterization,
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationReview of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases
Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationChanges in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationADENOCARCINOMA OF THE PROSTATE
Ref : ADENOCARCINOMA OF THE PROSTATE Div. of Urology, Dept. Surgery Medical Faculty, University of Sumatera Utara Clinical Manual of Urology, (Philip M. Hanno et al eds), McGraw-Hill Int ed, 3 rd ed, 2001
More informationJournal of American Science 2018;14(1)
Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits Mohamed F. Sheta 1, MD, Esam A. Abo-Zena 1, MD and Mohamed H. Radwan 2, MD 1 Department of Clinical Oncology,
More informationBJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent
21 THE AUTHORS; 21 Urological Oncology DETERMINANTS OF SURVIVAL IN PSA-RECURRENT PROSTATE CANCER AFTER PROSTATECTOMY ANTONARAKIS ET AL. BJUI Long-term overall survival and metastasis-free survival for
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More informationThe Natural History of Noncastrate Metastatic Prostate Cancer after Radical Prostatectomy
european urology 51 (2007) 940 948 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Natural History of Noncastrate Metastatic Prostate Cancer after Radical
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationErectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer. William M. Mendenhall, MD
Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer William M. Mendenhall, MD Meta-Analysis of Probability of Maintaining Erectile Function after Treatment of Localized Cancer Treatment
More informationOpen clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
More informationVol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10
25 Vol. 36, pp. 25 32, 2008 T1-3N0M0 : 20 2 18 T1-3 N0M0 1990 2006 16 113 59.4-70 Gy 68 Gy 24 prostate-specific antigen PSA 1.2 17.2 6.5 5 91 95 5 100 93 p 0.04 T3 PSA60 ng ml 68 Gy p 0.0008 0.03 0.04
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationRadiation therapy for localized prostate cancer is a main form of therapy
MANAGEMENT OF RADIATION FAILURE IN PROSTATE CANCER Selection of Salvage Cryotherapy Patients Aaron E. Katz, MD, Mohamed A. Ghafar, MD Department of Urology, College of Physicians & Surgeons of Columbia
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More informationWhat Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).
What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationProstate Cancer: Is There Standard Treatment? Who has prostate cancer? In this article:
Focus on CME at l Université de Montréal Prostate Cancer: Is There Standard Treatment? Pierre I. Karakiewicz, MD, FRCSC; Paul Perrotte, MD, FRCSC; Fred Saad, MD, FRCSC In this article: 1. Risk factors
More informationORIGINAL INVESTIGATION. Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans. having prostate cancer, assessment
ORIGINAL INVESTIGATION Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans Edward M. Uchio, MD; Mihaela Aslan, PhD; Carolyn K. Wells, MPH; Juan Calderone, MD; John Concato, MD, MS, MPH
More informationNavigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News
Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools
More informationHeterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationAmbulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer
Ambulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer Luigi Benecchi, Anna Maria Pieri, Carmelo Destro Pastizzaro, and Michele Potenzoni OBJECTIVES METHODS RESULTS CONCLUSIONS
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationThe Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy. Dr. Matt Andrews Supervisor: Dr. David Bowes
The Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy Dr. Matt Andrews Supervisor: Dr. David Bowes Objectives Discuss the evidence for adjuvant radiotherapy (ART) EORTC, SWOG, ARO Current
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationRADICAL PROSTATECTOMY IS ONE
ORIGINAL CONTRIBUTION Risk of Prostate Cancer Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy Stephen J. Freedland, MD Elizabeth B. Humphreys, BS Leslie A. Mangold, MS Mario
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationAnatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy specimens
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Anatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationTHE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE BIOPSIES IN IMPROVING THE DIAGNOSTIC ABILITY IN PROSTATE CANCER
Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 27 (3): 222-226, May - June, 2001 THE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationDate of preparation- January 2018 Janssen Biotech, Inc /18 em Reporter s guide to. prostate cancer
Date of preparation- January 2018 Janssen Biotech, Inc. 2018 02/18 em-01856 Reporter s guide to prostate cancer What is the prostate? The prostate is a gland located below the bladder, wrapped around the
More information